220394-84-3

Upstream product

• 169466-57-3 N-methyl-(2-phenylpent-4-enyl)amine 
• 169466-55-1 (S)-2-phenylpent-4-enoic acid, N-methyl amide 
• 76403-12-8 2-Phenyl-4-pentenoyl chloride 
• 1575-70-8 2-phenyl-pent-4-enoic acid 
• 103-82-2 phenylacetic acid 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 220394-85-4 (R,S)-N-(2-Phenyl-4-oxobut-1-yl)-N-methylbenzene-sulfonamide 
• 209349-04-2 C₂₉H₃₄N₂O₂S₂ 

Relevant academic research and scientific papers

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

(2S)-2-(3,4-Dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2 ,3-dihydrobenzthiophene-3,4′-piperidin-1′yl)]butane S-oxide (3) has been identified as a potent CCR5 antagonist lead structure having an IC50 = 35 nM. Herein, we describe the structure-activity relationship studies directed toward the requirement for and optimization of the C-2 phenyl fragment. The phenyl was found to be important for CCR5 antagonism and substitution was limited to small moieties at the 3-position (13 and 16: X = H, 3-F, 3-Cl, 3-Me).

CYCLIC AMINE MODULATIONS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to cyclic amines of the formula I: STR1 (wherein R 1, R 2, R 3, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.